Modules

The online course consists of 10 modules with pre- and post-tests.

Each module also has a feedback survey - completing these is a great help to us so we can improve and learn for our future online courses.

Module overview
Module 1

Mark Ratain, MD

Clinical and economic importance of optimizing dose
Mark Ratain, The University of Chicago, USA

Module 2

Magnus Ingelman-Sundberg, PhD, BSc.Med

Placing preclinical drug metabolism and pharmacokinetic data in context
Magnus Ingelman-Sundberg, Karolinska Institutet, Sweden

Module 3

Ruth Plummer, MD

Redefining the primary objective of phase 1 trials
Ruth Plummer, Newcastle University, UK

Module 4

Jaap Verweij, MD, PhD

Clinical endpoints useful for guiding early clinical development
Jaap Verweij, Erasmus Medical Centre, the Netherlands

Module 5

Lena Friberg, PhD

Pharmacometrics for the non-pharmacometrician
Lena Friberg, Uppsala University, Sweden

Module 6

Magnus Ingelman-Sundberg, PhD, BSc.Med

Using genetic and pharmacokinetic data from early clinical trials to guide subsequent clinical development
Magnus Ingelman-Sundberg, Karolinska Institutet, Sweden

Module 7

Mark Ratain, MD

Optimizing the use of pharmacodynamic biomarkers
Mark Ratain, The University of Chicago, USA

Module 8

Jaap Verweij, MD, PhD

Trial designs for the development of combinations of an investigational drug and a marketed drug
Jaap Verweij, Erasmus Medical Centre, the Netherlands

Module 9

Ruth Plummer, MD

Challenges for the development of immunotherapy drugs and combinations
Ruth Plummer, Newcastle University, UK

Module 10

Lena Friberg, PhD

Use of clinical trial simulation in oncology drug development
Lena Friberg, Uppsala University, Sweden